March 25, 2024
Eisai said on March 22 that the regulatory review of its Alzheimer’s disease drug lecanemab by a key European Medicines Agency (EMA) panel has been postponed due to procedural reasons. The deliberation process of lecanemab was delayed because the EMA...read more